Levornidazole disodium phosphate solvent compound, preparation method therefor, and use thereof
By introducing crystalline methanol and tetramolecules of water of crystallization into the disodium levonornidazole phosphate hydrate, a new solvent compound crystal form is formed, which solves the problem of insufficient stability and purity of disodium levonornidazole phosphate. This enables the preparation of disodium levonornidazole phosphate raw material with higher stability and purity, which is suitable for formulations against anaerobic bacteria and antiprotozoal infections.
Patent Information
- Application Number
- PCT/CN2024/090739
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-06
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-14
AI Technical Summary
The existing levofloxacin phosphate disodium hydrate has poor stability, and its poor water solubility leads to insufficient formulation stability and purity, affecting clinical application.
By introducing crystalline methanol and tetramolecules of water of crystallization into the disodium hydrate of levonornidazole phosphate, a new solvent compound crystal form is formed. The methanol molecule forms a coordinate bond with sodium, replacing the position of the water molecule, thus forming a more stable crystal.
It improves the stability and purity of levonornidazole phosphate disodium and reduces the impurity content, making it suitable for preparing high-purity levonornidazole phosphate disodium raw material for formulations against anaerobic bacteria and antiprotozoal infections.
Smart Images

Figure CN2024090739_14112024_PF_FP_ABST
Abstract
Description
A solvent compound of levonidazole disodium phosphate and its preparation method and use
[0001] This application claims priority to the Chinese patent application filed with the Patent Office of China on May 6, 2023, with application number 202310498951.5 and invention name “A new solvent compound of levonidazole disodium phosphate, its preparation method and use”, the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The present invention belongs to the field of crystallization of chemical substances, and in particular relates to a new solvent compound of levornidazole disodium phosphate, a preparation method and uses thereof, and a new crystal form of levornidazole disodium phosphate. Background Art
[0003] Ornidazole, a nitroimidazole antibacterial drug, has been widely used against anaerobic and antiprotozoal infections. It is a third-generation nitroimidazole derivative developed after metronidazole, offering enhanced efficacy, a shorter treatment course, improved tolerability, and wider distribution in the body. Ornidazole's antimicrobial activity is achieved through the reduction of the nitro group in its molecular formula to an amino group in an anaerobic environment or through free radical interaction with cellular components, leading to the death of microorganisms.
[0004] Ornidazole is mostly used clinically in the form of large-volume injections. It has extremely poor water solubility and a low melting point. When it is made into an infusion preparation, it requires strong acidity, which can easily cause phlebitis in patients when taking the drug. In addition, the toxic degradation product 2-methyl-5-nitroimidazole is highly toxic during high-temperature sterilization of the infusion, which brings great safety risks to clinical use.
[0005] Levo-ornidazole, the L-enantiomer of ornidazole, has similar therapeutic effects to ornidazole. Furthermore, it has a much lower central nervous system inhibitory effect than ornidazole, resulting in significantly fewer side effects during use. This makes it highly valuable as people continue to demand higher levels of drug safety.
[0006] To address the poor water solubility of ornidazole products, domestic researchers have modified their structures by phosphoesterification. The structure of L-ornidazole phosphate was proposed in patent CN200610166893.2, and further, the structure of L-ornidazole disodium phosphate pentahydrate was proposed in patent CN200710188487.0. In subsequent research, researchers proposed a crystalline form of L-ornidazole disodium phosphate heptahydrate and its preparation method in CN201910115156.7.
[0007] In order to solve the shortcoming of poor stability of levornidazole disodium phosphate hydrate, further research on levornidazole disodium phosphate hydrate is needed.
[0008] Summary of the Invention
[0009] The present invention provides a new solvent compound of levornidazole disodium phosphate, a preparation method thereof, and uses thereof. The invention aims to provide a new solvent compound of levornidazole disodium phosphate with a stable spatial structure and a crystal form thereof, which can support the acquisition of levornidazole disodium phosphate with higher purity and provide a new raw material selection with better stability for the preparation of levornidazole disodium phosphate preparations.
[0010] The levonidazole disodium phosphate solvent compound of the present invention has the following structural formula:
[0011] It contains one molecule of crystalline methanol and four molecules of crystalline water.
[0012] One of the main characteristics of the levornidazole disodium phosphate solvent compound mentioned in the present invention is that it contains one molecule of crystalline methanol.
[0013] Another characteristic of the levornidazole disodium phosphate solvent compound described herein is that it contains four molecules of crystalline water. Compared to crystalline methanol, the presence of multiple crystalline water molecules can lead to slight loss or gain of crystalline water depending on the ambient temperature and humidity, due to differences in binding energy. Therefore, states with three or five crystalline water molecules should be considered protected by this patent.
[0014] The inventors of the present invention unexpectedly obtained a new solvent compound crystal form of levornidazole disodium phosphate during their research on levornidazole disodium phosphate. The levornidazole disodium phosphate solvent compound crystal form is different from the existing hydrate crystal form. It is a crystal that is completely different from the existing hydrate with the participation of methanol solvent. The inventors of the present invention found that the formation and existence of this crystal can remove some water-soluble impurities in the original compound and obtain levornidazole disodium phosphate with higher purity. The inventors of the present invention also found that compared with conventional hydrate crystals, levornidazole disodium phosphate in the form of this crystal has higher stability. The levornidazole disodium phosphate solvent compound crystal form described in the invention is a key process intermediate and has extremely important practical value in obtaining high-purity and high-stability levornidazole disodium phosphate. As a crystal form with superior stability, it provides a new application option with stability advantages for the application of this raw material.
[0015] The levornidazole disodium phosphate solvent compound of the present invention usually exists in the form of crystals, and its crystal form has the structural unit shown in FIG2 .
[0016] The present invention provides single crystal crystallographic structure parameters and structure refinement parameters of a crystalline form of a levoornidazole disodium phosphate solvent compound, as follows:
[0017] The test data is only one kind of description of the test of this product. The data may vary slightly according to different test conditions and should still be understood as within the scope of protection of this patent.
[0018] The present invention also provides an X-ray powder diffraction pattern and characteristic peak data of the crystalline form of the levornidazole disodium phosphate solvent compound.
[0019] The solvent compound may further have characteristic peaks at these 2θ angle positions: 6.2, 11.7, 12.4, 13.6, 15.2, 15.6, 15.9, 18.2, 18.4, 19.9, 22.1, 23.5, 23.9, 24.3, 24.8, 26.8, 27.1, 27.7, 31.2, 32.2, 33.5.
[0020] The crystal characteristic peaks in this invention are expressed using methods commonly used in the art. Typically, an error of 0.2° is permitted when accurate to 0.1°. In actual measurements, larger deviations may occur due to particle size, sample height, preferred orientation, or sample transparency, but these deviations should still be considered within the scope of this patent.
[0021] The levonidazole disodium phosphate solvent compound mentioned in the present invention refers to a levonidazole disodium phosphate solvent compound containing a methanol solvent, specifically a levonidazole disodium phosphate crystal containing one molecule of crystalline methanol and four molecules of crystalline water, which is a structure with a stable crystal lattice. Compared with the currently available pentahydrate, hexahydrate and heptahydrate, it has better stability. The results of the stability test show that when placed under the same conditions, the degree of increase in its impurities is significantly lower than that of the hydrate crystal form without methanol.
[0022] The levornidazole disodium phosphate solvent compound mentioned in the present invention can be obtained in the following solvent system, wherein the solvent includes one or more of methanol, dichloromethane, ethyl acetate, acetone, and ethanol.
[0023] Generally, the solvent compound mentioned in the present invention can be prepared by the following process: taking levornidazole disodium phosphate (hydrate), adding 6 to 10 times (W / W) amount of anhydrous methanol to dissolve, adding 0.1% to 1% (W / V) activated carbon to decolorize for 20 minutes, filtering, stirring, and then dropwise adding 5 to 15 times (W / W) amount of dichloromethane (acetone, ethanol, ethyl acetate) to crystallize for 1 to 4 hours, filtering with suction, and drying the filter cake at 20°C to 30°C for 3 hours. The levornidazole disodium phosphate solvent compound is obtained.
[0024] During the process of obtaining the levornidazole disodium phosphate solvent compound mentioned in the present invention, it was unexpectedly discovered that the addition of appropriate water can effectively promote the formation of crystals. In the solvent system described above, increasing the use of water can more effectively and rapidly form levornidazole disodium phosphate crystals, and can even effectively reduce the amount of organic solvent used, thereby obtaining a better crystalline product.
[0025] Previously, it was believed that levornidazole disodium phosphate hydrate had good solubility in both water and methanol, and it was unimaginable to obtain a precipitate in a mixture of these two readily soluble solvents. However, during the process of obtaining the solvate, it was surprisingly discovered that by controlling the methanol / water ratio, levornidazole disodium phosphate could be successfully precipitated as a solvate. Furthermore, the resulting solvate exhibited good solubility in both water and methanol alone.
[0026] Therefore, the solvent compound mentioned in the present invention can also be prepared by the following process: take levornidazole disodium phosphate (hydrate), add 6 to 10 times (W / W) of anhydrous methanol to dissolve it, add 0.1% to 1% (W / V) activated carbon to decolorize it for 20 minutes, filter it, stir the filtrate, add 0.1 to 2.0 times (W / W) of water in the amount of the feed, and then add 5 to 15 times (W / W) of dichloromethane (acetone, ethanol, ethyl acetate) in the amount of the feed to crystallize it for 1 to 4 hours, filter it with suction, and dry the filter cake at 20°C to 30°C for 3 hours to obtain the levornidazole disodium phosphate solvent compound.
[0027] We can even use methanol and water alone to obtain a solvate of levornidazole disodium phosphate: Take levornidazole disodium phosphate (hydrate), add 6-10 times the amount (w / w) of anhydrous methanol, stir to dissolve at room temperature, filter, dropwise add 0.1-2.0 times the amount of water, stir evenly, and crystallize. After complete crystallization, filter, and air-dry the filter cake at 25°C to obtain the finished product.
[0028] In the process of the present invention, the solvent compound of levonidazole disodium phosphate is gradually precipitated by adding water to the methanol solution after filtration. Within the specified range, as the amount of water added increases, the amount of solvent compound precipitated increases. The amount of water added is limited to 0.1-2.0, and the lower limit here is 0.1 only to distinguish it from the case where no water is added. The upper limit is 2.0, which only means that the crystallization process has a higher yield under this addition amount, and it does not mean that the solvent compound cannot be obtained if the amount of water added is higher than 2.0 times. Therefore, in practical applications, this limit range should be understood as not being a strict limit. When the amount of water added is within the range of 0 to 2.0, or even when the amount of water added exceeds 2.0 times, it should also be understood as being within the scope of protection of this patent.
[0029] Although the solubility of levornidazole disodium phosphate in water is 10 to 20 times that in methanol, it is generally believed that the addition of water can increase the solubility of levornidazole disodium phosphate. However, the addition of water in this process is not intended to increase the solubility of levornidazole disodium phosphate. During the crystallization of levornidazole disodium phosphate, we realized that the addition of water here can promote the precipitation of levornidazole disodium phosphate solvate. This unusual phenomenon is due to the unique properties of levornidazole disodium phosphate solvate. Although difficult to understand, it should be recognized that this peculiar crystallization phenomenon.
[0030] The amount of solvent used in the process of preparing the disodium ornidazole phosphate solvent compound of the present invention is specified, and it should be understood as the reasonable amount determined under current technical conditions. It can be understood by those skilled in the art that, outside the specified range, additional solvents that promote precipitation, including but not limited to the amount of methanol, dichloromethane, acetone, and ethyl acetate, can be added to obtain the target solvent compound. In addition, the solvent used for crystallization is increased in a fixed or non-fixed ratio so as to exceed the range of the times described in the present invention, which should also be understood as being within the scope of protection of this patent.
[0031] In the preparation method mentioned in the present invention, the addition of activated carbon to adsorb and remove impurities from the solution is a routine operation, which has no essential impact on the process. Obviously, the process of removing or making appropriate changes to this operation step should be understood to be within the scope of protection of this patent.
[0032] The core feature of the preparation process described in the present invention is that after the sample is dissolved in anhydrous methanol and inorganic impurities are removed, an appropriate amount of water is added to precipitate crystals as a solvent compound. An organic solvent that promotes precipitation can then be added to further improve the yield. To achieve the purpose of removing inorganic impurities, the introduction of water should be avoided during the dissolution process. In this step, methanol, preferably anhydrous methanol, can be used as the solvent. When using analytically pure or industrial-grade methanol, the solvent moisture content should be strictly controlled. In a methanol / water mixture with a higher moisture content, the efficiency of removing inorganic salts will rapidly decrease, making the desalination purpose impossible.
[0033] Another feature of the preparation process mentioned in the present invention is that the addition of water can effectively enhance the formation of crystals.
[0034] Another characteristic of the preparation process described herein is that the methanol / water / precipitation-promoting solvent is added in stages. As a sequential process, desalination and crystallization are performed in stages, with each stage having its own distinct value. Therefore, this sequential process is a hallmark of the preparation process.
[0035] The new crystal form of levornidazole disodium phosphate obtained by the present invention has unique solubility properties and unusual stability.
[0036] The levornidazole disodium phosphate solvate mentioned in the present invention differs from existing hydrate crystals in that, when forming crystals, a molecule of methanol replaces the water. The oxygen in the methanol molecule forms a coordination bond with the sodium in the levornidazole disodium phosphate, ultimately forming a new and surprisingly stable crystal. Due to the difference between the methanol molecule and the water molecule, a new crystalline form is produced that is completely different from the existing pentahydrate, hexahydrate, and heptahydrate. Due to the introduction of crystalline methanol, the solvate exhibits superior stability characteristics compared to the original hydrate crystal form.
[0037] The novel solvate crystalline form of levornidazole phosphate disclosed herein can be used to prepare levornidazole disodium phosphate of higher purity. During the formation of the novel crystalline form, inorganic salt impurities in the compound can be effectively removed through orderly operations, thereby obtaining higher-purity phosphoric acid for ornidazole disodium.
[0038] The levornidazole disodium phosphate solvent compound of the present invention has better stability, can solve the shortcoming of poor stability of levornidazole disodium phosphate hydrate, and can be used in preparations with higher requirements on the stability of raw materials.
[0039] The levornidazole disodium phosphate solvent compound of the present invention can be used to prepare a suitable dosage form for resisting anaerobic bacteria infection and antiprotozoal infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] FIG1 is a crystal photograph of a methanol solvent compound of levornidazole disodium phosphate.
[0041] FIG2 is a schematic diagram of a single crystal structural unit of a methanol solvent compound of levornidazole disodium phosphate.
[0042] FIG3 is a schematic diagram of the molecular stacking structure of the single crystal structure of levonidronate disodium phosphate methanol solvent compound (a, b, c-axis).
[0043] FIG4 is an X-ray diffraction pattern of levornidazole disodium phosphate methanol solvent compound.
[0044] FIG5 is a comparison diagram of crystal photos of levornidazole disodium phosphate heptahydrate (refer to patent CN109748934).
[0045] FIG6 is a comparison diagram of X-ray diffraction of levornidazole disodium phosphate heptahydrate. DETAILED DESCRIPTION
[0046] Comparative Example 1: The raw materials of levornidazole disodium phosphate used in Examples 1-14 are products from the same batch prepared using the technology disclosed in our company's patent CN200610166893.2.
[0047] Comparative Example 1
[0048] Take 20g of levornidazole disodium phosphate, add 200g of a mixed solvent (water:ethanol = 1:20, V / V) to dissolve the clear solution, filter, add a small amount of sample as a seed crystal, wait for solid precipitation at 5-25°C, filter, and dry the filter cake at 20-30°C to obtain 15.8g of levornidazole disodium phosphate heptahydrate. (Contains ethanol: 0.03%, water 27.3%). Its X-ray powder diffraction pattern is shown in Figure 6. Upon comparison, it is consistent with the crystal form described in patent CN201910115156.7.
[0049] Example 1
[0050] 50 g of levonidazole disodium phosphate hydrate was added to 300 g of anhydrous methanol and dissolved at room temperature. 1.5 g of activated carbon was added for decolorization at room temperature for 20 minutes. The mixture was filtered and stirred. 662.5 g of dichloromethane was then added dropwise. Crystallization occurred over 3 hours. The mixture was then filtered with suction and the filter cake was dried at 30°C for 3 hours. 42.0 g of the finished product (containing 8.1% methanol, no dichloromethane, and 16.1% water) was obtained.
[0051] Example 2
[0052] Take 50 g of ornidazole disodium phosphate hydrate, add 380 g of anhydrous methanol to dissolve at room temperature, decolorize with 1.5 g of activated carbon at room temperature for 20 min, filter, stir the filtrate, add 813 g of acetone dropwise, add and crystallize for 3 hours, filter, and dry the filter cake at 30 ° C for 3 hours to obtain 37.9 g of the finished product (containing methanol: 7.6%; acetone: 0.04%; water: 15.4%).
[0053] Example 3
[0054] Take 50 g of ornidazole disodium phosphate hydrate, add 396 g of anhydrous methanol to dissolve, decolorize with 1.5 g of activated carbon, filter, add about 902 g of ethyl acetate to the filtrate for crystallization, stir for 3 hours, filter, and dry the filter cake at 25°C to obtain 40.5 g of the finished product (containing methanol: 8.2%; ethyl acetate: 0.02%; water: 16.5%).
[0055] Example 4
[0056] Take 100 g of levonidazole disodium phosphate hydrate, add 750 g of anhydrous methanol to dissolve, decolorize with 3.0 g of activated carbon for 20 min, filter, add 800 g of dichloromethane dropwise to the filtrate for crystallization, stir for 3 hours, filter, and dry the filter cake at 30 ° C for 3 hours to obtain 77.6 g of the finished product (containing methanol: 7.6%; dichloromethane: 0.02%; water: 15.3%).
[0057] Example 5
[0058] Take 100 g of ornidazole disodium phosphate hydrate, add 1000 g of anhydrous methanol to dissolve, decolorize with 3.0 g of activated carbon for 20 min, filter, add 1500 g of dichloromethane dropwise to the filtrate for crystallization, stir for 4 hours, filter, and dry the filter cake at 30 ° C for 3 hours to obtain 37.9 g of the finished product (containing methanol: 7.8%; dichloromethane: 0.01%; water: 16.4%).
[0059] Example 6
[0060] Take 100 g of ornidazole disodium phosphate hydrate, add 800 g of anhydrous methanol, dissolve at room temperature, decolorize 3.0 g of activated carbon at room temperature for 20 minutes, filter, add 10.0 g of water to the filtrate, add 800 g of dichloromethane dropwise, continue stirring, filter after complete crystallization, and dry the filter cake at 30°C for 3 hours to obtain 86.5 g of the finished product (containing methanol: 7.7%; dichloromethane: 0.01%; water: 15.6%).
[0061] Example 7
[0062] Take 100 g of ornidazole disodium phosphate hydrate, add 800 g of anhydrous methanol, dissolve at room temperature, decolorize 3.0 g of activated carbon at room temperature for 20 min, filter, add 50 g of water to the filtrate, stir, add 800 g of dichloromethane dropwise, continue stirring and crystallize, filter after complete crystallization, and dry the filter cake at 30 ° C for 3 hours to obtain 87.9 g of the finished product (containing methanol: 8.1%; acetone: no; water: 15.0%).
[0063] Example 8
[0064] Take 100 g of ornidazole disodium phosphate hydrate, add 800 g of methanol, dissolve at room temperature, add 3.0 g of activated carbon to decolorize at room temperature for 20 minutes, filter, add 200.0 g of water to the filtrate, add 800 g of dichloromethane dropwise, continue stirring and crystallize, filter after complete crystallization, and dry the filter cake under reduced pressure at 25°C to obtain 35.9 g of the finished product (containing methanol: 7.9%; dichloromethane: no; water: 16.5%).
[0065] Example 9
[0066] Take 100 g of ornidazole disodium phosphate hydrate, add 800 g of methanol, dissolve at room temperature, add 3.0 g of activated carbon to decolorize at room temperature for 20 minutes, filter, add 60 g of water to the filtrate, add 800 g of anhydrous ethanol to crystallize, continue stirring and crystallization, filter after crystallization is complete, and air-dry the filter cake at 25°C to obtain 88.5 g of the finished product (containing methanol: 7.6%; ethanol: 0.04%; water: 15.8%).
[0067] Example 10
[0068] Take 100 g of levonidazole disodium phosphate, add 800 g of methanol, dissolve at room temperature, add 3.02 g of activated carbon to decolorize at room temperature for 20 minutes, filter, add 100 g of water to the filtrate, add 600 g of acetone to crystallize, continue stirring and crystallization, filter after crystallization is complete, and air-dry the filter cake at 25°C to obtain 87.4 g of the finished product (containing methanol: 8.1%; acetone: no; water: 16.4%).
[0069] Example 11
[0070] Take 100 g of levonidazole disodium phosphate, dissolve it in 800 g of methanol, 10 g of acetone, stir and dissolve at room temperature, add 3.0 g of activated carbon for decolorization, add 100 g of water, and then add 800 g of anhydrous ethanol dropwise, continue stirring and crystallize, filter after crystallization is complete, and air-dry the filter cake at 25 ° C to obtain 88.9 g of the finished product (containing methanol: 7.8%; acetone: no; ethanol: 0.02%; water: 15.9%).
[0071] Example 12
[0072] Take 100g of levonidazole disodium phosphate, add 750g of methanol, stir at room temperature to dissolve, filter, add 20g of water, stir evenly, and let stand to crystallize. After complete crystallization, filter, and air-dry the filter cake at 25°C. 28.1g of the finished product (methanol: 7.7%; water: 16.9%) is obtained.
[0073] Example 13
[0074] Take 100g of levonidazole disodium phosphate, add 750g of methanol, stir at room temperature to dissolve, filter, add 100g of water, stir evenly, and crystallize. After crystallization is complete, filter, and air-dry the filter cake at 25°C. 71.3g of the finished product (containing 7.9% methanol and 15.1% water) is obtained.
[0075] Example 14
[0076] Take 100 g of levornidazole disodium phosphate, add 900 g of methanol to dissolve, stir at room temperature to dissolve, add 1.0 g of activated carbon to decolorize, add 100 g of water, and then add 800 g of anhydrous ethanol / acetone mixed solution (1:1, W / W) dropwise, continue stirring to crystallize, filter after crystallization is complete, and air-dry the filter cake at 25°C to obtain 85.7 g of the finished product (containing methanol: 7.5%; acetone: 0.01%; ethanol: 0.03%; water: 15.5%).
[0077] Example 15
[0078] Comparison of the solubility of levornidazole disodium phosphate in methanol solvent and its hydrate.
[0079] The solubility of the solvent compound prepared in Example 13 and the levonidazole disodium phosphate heptahydrate prepared in Comparative Example 1 in different solvents was investigated. The results are as follows:
[0080] The results showed that the solubility of levonidazole disodium phosphate solvent compound and hydrate in water and methanol was completely different, and their solubility in ethanol was also different. In hypertonic DMSO, their solubility was similar.
[0081] Example 16
[0082] Comparison of free phosphate in methanol solvent compound and hydrate of levonidazole disodium phosphate
[0083] Test sample:
[0084] Seven crystal waters of levonidazole disodium phosphate: Comparative Example 1
[0085] Six crystal waters of levonidazole disodium phosphate: prepared according to our patent CN201610125343.X
[0086] Five crystal waters of levonidazole disodium phosphate: prepared according to our patent CN200710188487.0
[0087] Levoornidazole disodium phosphate solvent compound: Examples 1 to 14
[0088] Determination method: Accurately weigh 20 mg of levonidazole disodium phosphate into a 25 mL volumetric flask and add 15 mL of water to dissolve. Separately, take 4.0 mL of standard phosphate solution [accurately weigh 0.35 g of potassium dihydrogen phosphate dried at 105°C for 2 hours into a 1000 mL volumetric flask, add 10 mL of sulfuric acid solution (3→10) and an appropriate amount of water to dissolve, dilute to the mark, and shake well; dilute 10-fold before use] and place into another 25 mL volumetric flask and add approximately 11 mL of water. Accurately add 2.5 mL of ammonium molybdate sulfuric acid test solution and 1 mL of 1-amino-2-naphthol-4-sulfonic acid solution to each, add water to the mark, shake well, and incubate at 20°C for 30 to 50 minutes. Measure the absorbance at a wavelength of 740 nm using UV-visible spectrophotometry to calculate the free phosphate content. Results are shown in Table 1.
[0089] Table 1: Free phosphate test results in Example 16
[0090] The above results show that the free phosphate content of the methanol solvent compound of levornidazole disodium phosphate prepared using the present invention is significantly lower than that of Comparative Example 1. By preparing the solvent compound of the present invention, the residual free phosphate in the original product can be effectively removed, thereby improving the purity of the finished product. As an important intermediate in the purification process, it will have important use value in obtaining high-purity compounds.
[0091] Example 17
[0092] Comparative study on the stability of levonidazole disodium phosphate methanol solvent compound and hydrate
[0093] The levornidazole disodium phosphate solvent compounds (Examples 7, 9, 12, and 13), the levornidazole disodium phosphate heptahydrate prepared in Comparative Example 1, and the pentahydrate and hexahydrate compounds mentioned in Example 16 were placed at 60° C. and the stability indicators of different crystalline forms for 10 days were examined, including appearance, moisture, related substances, and content.
[0094] Appearance: visual inspection
[0095] Moisture: Moisture determination method (Fischer method)
[0096] Related substances: High performance liquid chromatography (self-control method without correction factor)
[0097] Assay: High performance liquid chromatography (external standard method)
[0098] The measurement results are shown in Table 2
[0099] The results showed that the solvate of levornidazole disodium phosphate was significantly more stable than its hydrate. The introduction of methanol as a solvent resulted in a more stable lattice structure, resulting in a new crystalline form with improved stability compared to conventional hydrate crystals. The solvate crystalline form described in the present invention provides a superior stability alternative to levornidazole disodium phosphate.
[0100] Example 18
[0101] Preparation of levonidazole disodium phosphate for injection
[0102] Prescription 1:
[0103] 400g of levonidazole disodium phosphate solvent compound (calculated as levonidazole disodium phosphate)
[0104] 110g citric acid
[0105] Water for injection 2L
[0106] Produced 1000 bottles
[0107] Prescription 2:
[0108] 400g of levornidazole disodium phosphate heptahydrate (calculated as levornidazole disodium phosphate)
[0109] 110g citric acid
[0110] Water for injection 2L
[0111] Produced 1000 bottles
[0112] Prescription 3:
[0113] 400g of levornidazole disodium phosphate hexahydrate (calculated as levornidazole disodium phosphate)
[0114] 110g citric acid
[0115] Water for injection 2L
[0116] Produced 1000 bottles
[0117] Prescription 4:
[0118] 400g of levornidazole disodium phosphate pentahydrate (calculated as levornidazole disodium phosphate)
[0119] 110g citric acid
[0120] Water for injection 2L
[0121] Produced 1000 bottles
[0122] Take citric acid and add it to 0.16L of the prescribed amount of water for injection. After stirring to dissolve, continue to add the prescribed amount of levonidronate disodium phosphate solvent compound and stir. After it is completely dissolved, add 0.04L of water for injection and continue to stir evenly. Filter through a 0.22μm microporous filter membrane until the clarity meets the requirements.
[0123] The content of the intermediate levonidazole disodium phosphate was determined, and the fixed amount was dispensed into controlled vials, which were then half-stoppered and placed in a freeze dryer.
[0124] The plate temperature is set to -45°C, the cooling rate is 40°C / hour, and maintained for 4 hours;
[0125] Adjust the temperature to -30°C, heating rate 20°C / hour, and maintain for 2 hours;
[0126] Adjust the temperature to -20°C, heating rate to 20°C / hour, and maintain for 10 hours;
[0127] Adjust the temperature to -15°C, heating rate 20°C / hour, and maintain for 12 hours;
[0128] Adjust the temperature to -5°C, heating rate 10°C / hour, and hold for 0.5 hours;
[0129] The temperature was adjusted to 15°C, the heating rate was 5°C / hour, and maintained for 1 hour.
[0130] After the freeze-drying is completed, the plug is pressed and the cap is rolled to obtain levornidazole disodium phosphate for injection.
[0131] The levonidazole disodium phosphate for injection prepared from each of the above prescriptions was tested for appearance, moisture, residual solvent, phosphate, related substances, and content. The results are shown in Table 3.
[0132] Table 3: Freeze-drying test results of different formulations
[0133] In the finished lyophilized levonidazole disodium phosphate for injection, no residual solvent was detected in the different formulations. Phosphate residues were similar to those in the API, indicating that removing free phosphate from the raw materials can effectively reduce the impurity content in the product. No significant differences were observed in other indicators.
Claims
1. A solvent compound of levonidazole disodium phosphate as shown in formula I: in, The solvent compound of levonidazole disodium phosphate contains 1 molecule of methanol and 4 molecules of water.
2. The levonidazole disodium phosphate solvent compound according to claim 1, It is characterized in that The crystal system of this crystal form is orthorhombic, P212121 space group, and its unit cell parameters are used to calculate the unit cell volume: a=90°, b=90°, γ=90°, Its X-ray powder diffraction 2θ values have characteristic peaks at 6.2, 11.7, 12.4, 13.6, 15.2, 15.6, 15.9, 18.2, 18.4, 19.9, 22.1, 23.5, 23.9, 24.3, 24.8, 26.8, 27.1, 27.7, 31.2, 32.2, and 33.
5.
3. A method for preparing a crystalline form of a disodium ornidazole phosphate solvent compound, It is characterized in that The method comprises the following steps: taking levoornidazole disodium phosphate (hydrate), adding 6 to 10 times (W / W) amount of anhydrous methanol to dissolve, adding 0.1% to 1% (W / V) activated carbon to decolorize for 20 minutes, filtering, stirring the filtrate, dripping water in an amount of 0.1 to 2.0 times (W / W) amount of the feed, and then dripping a solvent in an amount of 5 to 15 times (W / W) amount of the feed for crystallization for 1 to 4 hours, suction filtering, and drying the filter cake at 20 to 30 degrees Celsius for 3 hours to obtain a levoornidazole disodium phosphate solvent compound.
4. The method for preparing the crystalline form of levonidazole disodium phosphate solvent compound according to claim 3, It is characterized in that The solvent used for crystallization is one or more of dichloromethane, ethanol, acetone and ethyl acetate.
5. The method for preparing the solvent compound of levonidazole disodium phosphate according to claim 3, It is characterized in that Crystallization was carried out in methanol; Preferably, water is added during the crystallization process as an auxiliary crystallization solvent.
6. A method for preparing a crystalline form of a disodium ornidazole phosphate solvent compound, It is characterized in that The method comprises the following steps: taking levoornidazole disodium phosphate (hydrate), adding 6 to 10 times (W / W) anhydrous methanol, stirring and dissolving at room temperature, filtering, dripping 0.1 to 2.0 times of the feed amount of water, stirring evenly, crystallizing, filtering after the crystallization is complete, and air-drying the filter cake at a temperature of 25°C to obtain the levoornidazole disodium phosphate solvent compound.
7. The method for preparing the levonidazole disodium phosphate solvent compound according to claim 6, It is characterized in that Crystallization was carried out in methanol.
8. The method for preparing the levonidazole disodium phosphate solvent compound according to claim 7, It is characterized in that Water was added as an auxiliary crystallization solvent during the crystallization process.
9. Use of the levoornidazole disodium phosphate solvent compound according to claim 1 or 2 in the preparation of high-purity levoornidazole disodium phosphate.
10. Use of the levornidazole disodium phosphate solvent compound according to claim 1 or 2 in the preparation of high-purity levornidazole disodium phosphate for injection.
Citation Information
Patent Citations
(s)-ornidazole disodium phosphate pentahydrate as well as preparation method and uses thereof
CN101177433A
Method for producing pentahydrate s-ornidazole disodium phosphate
CN105646580A
S-(-)-ornidazol disodium phosphate hexahydrate crystal form and preparation method thereof
CN107151257A
Method for preparing highly pure (S)-ornidazole phosphate disodium
CN107857779A
Novel solvocompound of S-ornidazole disodium phosphate as well as preparation method and application of solvocompound
CN116535440A
Cited By
Crystal form of S-ornidazole disodium phosphate and preparation method thereof
CN120004950A
